Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Nov;7(21):601.
doi: 10.21037/atm.2019.08.110.

Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?

Christelle de la Fouchardiere  1
Affiliations
Editorial

Treating BRAFV600E metastatic colorectal patients in 2019: a BEACON of hope?

Christelle de la Fouchardiere. Ann Transl Med. 2019 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: C de la Fouchardiere declared providing a consultancy role for Pierre Fabre, Roche, Amgen, Bayer, Lilly, BMS and Servier. C de la Fouchardiere has been involved as investigator in the BEACON study.

Comment on

References

    1. Venderbosch S, Nagtegaal ID, Maughan TS, et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014;20:5322-30. 10.1158/1078-0432.CCR-14-0332 - DOI - PMC - PubMed
    1. de la Fouchardière C, Cohen R, Malka D, et al. Characteristics of BRAF V600E Mutant, Deficient Mismatch Repair/Proficient Mismatch Repair, Metastatic Colorectal Cancer: A Multicenter Series of 287 Patients. Oncologist 2019. [Epub ahead of print]. 10.1634/theoncologist.2018-0914 - DOI - PMC - PubMed
    1. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015;16:1306-15. 10.1016/S1470-2045(15)00122-9 - DOI - PubMed
    1. Sorbye H, Dragomir A, Sundström M, et al. High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort. PLoS One 2015;10:e0131046. 10.1371/journal.pone.0131046 - DOI - PMC - PubMed
    1. Chu JE, Johnson B, Morris VK, et al. Population-based screening for BRAF V600E in metastatic colorectal cancer (mCRC) to reveal true prognosis. J Clin Oncol 2019;37:3579 10.1200/JCO.2019.37.15_suppl.3579 - DOI - PMC - PubMed